RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:$5.6 Billion move into big pharma by BerkshireMichel1234 wrote: A few years ago, Knight was doing at least a few deals annually for license agreement in Canada and the pipeline was increasing quickly. In the past two or three years, it was very quiet. There was almost no new similar license deal made by Knight for Canada. This is a little bit disappointing. I like the potential for Antibe and Profound, but it would be nice to continue to build the pipeline in Canada and worldwide.
Also, I think it would be optimal to have some consolidation in the sector for potential synergy. I don't follow every company in the sector, but I don't see how it could be optimal for a small company like Cipher to continue operating by itself. It is just a example.
Yes ... very good point Michel.
It's not like we don't have enough money to keep the deal-making going. Cash is not the problem.
We've been told that Amal is busy ... but ... busy doing what ?
We know COVID may have slowed down optimization of LATAM but it hasn't affected the acquisition strategy (according to Goodman) - but - it sure looks like it's slowed down.
The only logical explanation would be that they are working on much bigger deals - which take time.
Your example of Cipher is perfect and we don't know if Goodman finds that kind of deal to be possible or too expensive still ... so where might he be looking? If not Canada, is he looking at Mexico and South America? Is he looking on some other continent like South Africa ?
We just don't know but it does seem odd that things just slowed right down.
If the shelf prospectus is any indication, you'd think there are some big opportunities at hand - but - that's all speculation.